ATM and breast cancer: Lowry et al. [70] in a comparative modeling analysis demonstrated early annual MRI (age 30 to 35) with MRI and mammography starting at age 40 to decreased mortality associated with breast cancer by more than half (>50%) in women with germline ATM, CHEK2, and PALB2 mutations.